Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hongjing Jiang
Observed name:
H J Jiang
Institution:
Tianjin Medical University Cancer Institute and Hospital
Observed institutions:
Shanghai Jiao Tong University,
Ruijin Hospital,
Tianjin Medical University Cancer Institute and Hospital,
Tianjin Medical University
ORCID:
0000-0002-3849-964X
Observed ORCID:
0000-0002-3849-964X
OpenAlex ID:
A5111647278
A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial
2024
·
Xiaobin Shang
, Yongjie Xie
, et al.
·
Cancer Cell
·
73
Prognostic role of the pathological status following neoadjuvant chemoradiotherapy and surgery in esophageal squamous cell carcinoma
2025
·
Xiaofeng Duan
, Jie Yue
, et al.
·
BMC Cancer
·
9
PDF
Global Burden of Early‐Onset Esophageal Cancer From 1990 to 2021: A Systematic Analysis of the Global Burden of Disease Study 2021
2025
·
Guotian Pei
, Yuqing Huang
, et al.
·
Thoracic Cancer
·
6
PDF
Multi‐Institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma
2025
·
Fangdong Zhao
, Qifeng Wang
, et al.
·
Cancer Medicine
·
6
PDF
PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026
·
Yushang Yang
, Xiaolong Yan
, et al.
·
Clinical Cancer Research
·
3
PDF
Lysosome-escaping and nucleus-targeting nanomedicine for enhanced cancer catalytic internal radiotherapy
2025
·
Weiwei Su
, Han Wang
, et al.
·
European Journal of Nuclear Medicine and Molecular Imaging
·
3
Data from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026
·
Yushang Yang
, Xiaolong Yan
, et al.
Supplementary Figure S4 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026
·
Yushang Yang
, Xiaolong Yan
, et al.
Supplementary Figure S2 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026
·
Yushang Yang
, Xiaolong Yan
, et al.
Supplementary Figure S6 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026
·
Yushang Yang
, Xiaolong Yan
, et al.
Supplementary Figure S1 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026
·
Yushang Yang
, Xiaolong Yan
, et al.
Supplementary Figure S5 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026
·
Yushang Yang
, Xiaolong Yan
, et al.
Supplementary Figure S3 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026
·
Yushang Yang
, Xiaolong Yan
, et al.
Supplementary Material S2 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026
·
Yushang Yang
, Xiaolong Yan
, et al.
Supplementary Tables S1-S15 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026
·
Yushang Yang
, Xiaolong Yan
, et al.
Supplementary Material S1 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026
·
Yushang Yang
, Xiaolong Yan
, et al.
[The application of the en bloc resection for robot-assisted esophageal suspension-traction combined with the "four-edge" dissociation in the lymph node dissection of left recurrent laryngeal nerve of esophageal squamous cell carcinoma].
2026
·
C G Chen
, J Yue
, et al.
·
PubMed
379. Health-related Quality of Life Following Robotic Versus Thoracoscopic Esophagectomy: a Prespecified Secondary Analysis of the Multicenter Revate Trial
2025
·
Yin-Kai CHAO
, Zhigang Li
, et al.
·
Diseases of the Esophagus
PDF
Causal relationship between circulating immune cells and the risk of esophageal cancer: a Mendelian randomization study
2025
·
Shangren Wang
, Ruizhen Wang
, et al.
·
Discover Oncology
PDF
Show more works
View as search
Works count:
21
Citation count:
100
H-index:
4
I10-index:
1
Year
Topic
Type